Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > While we're at it ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(448)
•••
Comment by davgroon May 26, 2022 10:57am
148 Views
Post# 34709044

RE:While we're at it ...

RE:While we're at it ...
MrMugsy wrote: Any bets on when his troll friends show up?
Usually right behind him ... just a couple steps behind.

Same guy or similar ?


Stutters fits the mold of your typical Stockhouse Internet troll.  He showed up on Stockhouse exactly 6 months ago and has only posted in the ATE board.  He shares nothing of value on this board and tries to start a "Flame War" with every post. 

I have learned to ignore trolls like him, unless of course you find his antics entertaining (like I do with the Dumpster340).  The other sure fire way of silencing a troll is to provide facts and evidence that proves them wrong.  I suspect stutters is a disgruntled ex-ATE shareholder who lost large and is now lashing out with the sole intent of provoking emotional responses from others.  Trolls feed on this type of response.

In hindsight, I could have made a fortune if I had invested in the manufacturer of "Troll B Gone".  Demand for their product is skyrocketing as the unabated rise in Internet trolls continues.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities